These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1591693)

  • 1. The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to autologous peripheral blood lymphocytes.
    Mizutani Y; Nio Y; Yoshida O
    Cancer; 1992 Jun; 69(12):2999-3007. PubMed ID: 1591693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation by cis-diamminedichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells.
    Mizutani Y; Nio Y; Yoshida O
    J Urol; 1992 Feb; 147(2):505-10. PubMed ID: 1732632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro enhancement of natural killer cell activity by BCG and the antagonistic inhibition of the susceptibility of K562 cells to lysis by peripheral blood lymphocytes in patients with urinary bladder tumor.
    Mizutani Y; Yoshida O
    Int J Urol; 1994 Mar; 1(1):49-56. PubMed ID: 7627838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation by the protein-bound polysaccharide PSK (krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer.
    Mizutani Y; Yoshida O
    J Urol; 1991 May; 145(5):1082-7. PubMed ID: 2016797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer.
    Mizutani Y; Nio Y; Fukumoto M; Yoshida O
    Cancer; 1992 Jan; 69(2):537-45. PubMed ID: 1728384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-activated peripheral blood lymphocytes and tumor infiltrating lymphocytes.
    Mizutani Y; Yoshida O; Miki T
    J Urol; 1999 Dec; 162(6):2170-5. PubMed ID: 10569614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
    Mizutani Y; Bonavida B; Nio Y; Yoshida O
    Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells in patients with bladder cancer.
    Mizutani Y; Okada Y; Yoshida O; Bonavida B
    Cancer Biother Radiopharm; 1996 Dec; 11(6):385-91. PubMed ID: 10851499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally administered streptococcal preparation, OK-432 augments the antitumor immunity of patients with gastric or colorectal cancer.
    Nio Y; Ohgaki K; Tsuchitani T; Imai S; Shiraishi T; Tobe T
    Biotherapy; 1990; 2(3):213-22. PubMed ID: 2206774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunocompetence of tissue infiltrating lymphocytes in bladder tumors.
    Tsujihashi H; Matsuda H; Uejima S; Akiyama T; Kurita T
    J Urol; 1988 Oct; 140(4):890-4. PubMed ID: 3262173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of PSK and its subfractions on peripheral blood lymphocytes mediated cytotoxicity against urinary bladder tumor cells.
    Mizutani Y; Nio Y; Yoshida O
    J Urol; 1992 Nov; 148(5):1571-6. PubMed ID: 1433570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
    Mizutani Y; Okada Y; Terachi T; Yoshida O
    J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Anticancer Res; 1990; 10(2A):441-6. PubMed ID: 2346317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells.
    Colotta F; Rambaldi A; Colombo N; Tabacchi L; Introna M; Mantovani A
    Br J Cancer; 1983 Oct; 48(4):515-25. PubMed ID: 6626452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction by OK-432 of the monolayer contact-mediated inhibition of human natural killer cell activity.
    Yagita M; Saksela E
    Immunol Lett; 1990 Sep; 25(4):347-53. PubMed ID: 2249878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy for renal cell carcinoma using IFN-gamma and OK-432: in vitro study.
    Muraki J
    Keio J Med; 1990 Mar; 39(1):21-5. PubMed ID: 2113148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432.
    Uchida A; Micksche M
    J Natl Cancer Inst; 1983 Oct; 71(4):673-80. PubMed ID: 6413742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral administration of OK-432 (picibanil). (8th report) clinical application: its immunomodulatory effects on the patients with gastrointestinal cancers].
    Nio Y; Ohgaki K; Tsuchitani T; Imai S; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Tobe T
    Nihon Gan Chiryo Gakkai Shi; 1989 Aug; 24(8):1607-15. PubMed ID: 2809385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced susceptibility of c-myc antisense oligonucleotide-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes.
    Mizutani Y; Bonavida B; Fukumoto M; Yoshida O
    J Immunother Emphasis Tumor Immunol; 1995 Feb; 17(2):78-87. PubMed ID: 7647959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.